降钙素基因相关肽基因体外转染人脐静脉内皮细胞

目的：观察逆转录病毒载体介导的降钙素基因相关肽（ｃａｌｃｉｔｏｎｉｎｇｅｎｅｒｅｌａｔｅｄｐｅｐｔｉｄｅ，ＣＧＲＰ）基因对人脐静脉内皮细胞的作用，探讨其应用于动脉粥样硬化和经皮腔内冠状动脉成形术后再狭窄基因治疗的可行性。方法：构建含有ＣＧＲＰｃＤＮＡ的逆转录病毒载体，体外转染人脐静脉内皮细胞。用ＲＴＰＣＲ及放射免疫法分析检测基因表达水平。应用细胞计数及流式细胞仪观察ＣＧＲＰ基因对内皮细胞生长的影响。结果：逆转录病毒载体能有效地将外源性基因导入血管内皮细胞并稳定表达。导入ＣＧＲＰ基因可以促进内皮细胞的分裂增殖，从而加速损伤内皮的修复。结论：ＣＧＲＰ基因有可能作为动脉粥样硬化及再狭窄基因治疗的有效候选基因

Expression of calcitonin gene-related peptide in human umbilical veinendothelial cells transfected with retroviral vectors in vitro

Objective: To investigate the effect of calcitonin gene related peptide (CGRP) gene mediated by recombinant retroviral vector on human umbilical vein endothelial cells(HUVEC) and explore the possibility of using CGRP gene for gene therapy in atherosclerosis and restenosis. Methods: CGRP gene recombinant retroviral vector was constructed to transfect into HUVEC in vitro . The gene expression was detected by radioimmunoassay and RT PCR. The role of CGRP gene on HUVEC proliferation, viability and cell cycle were observed by cell counting and flow cytometry, respectively. Results: The CGRP gene could be effectively transferred into HUVEC and stably expressed. The expressed CGRP gene promoted the proliferation of HUVEC and might enhance the recovery of injured endothelium. Conclusion: CGRP gene can serve as one of the promising candidate gene for gene therapy in atherosclerosis and restenosis. Retroviral mediated CGRP gene transfer may be used to treat atherosclerosis and restenosis.